

Supplementary Table 2.

Mean percentages \pm SD of tumor infiltrates from immune cell subsets from the myeloid line obtained by flow cytometric analysis at day 6 after treatment onset. MDSCs: myeloid-derived suppressive cells,

	Monocytes (Ly6G ⁻ CD11b ⁺)	MDSCs (Gr1 ⁺ CD11b ⁺)	Granulocytes (Ly6G ⁺ CD11b ⁺)	Macrophages (F4/80 ⁺ CD11b ⁺)	mDCs (MHC-II ⁺ CD11c ⁺)
RT + PBS + IgG	33.8% \pm 12.9	2.9% \pm 2.0	1.0% \pm 0.3	2.1% \pm 1.8	4.4% \pm 1.8
RT + L19-IL2 + PBS	29.3% \pm 8.4	3.3% \pm 2.1	0.8% \pm 0.4	1.3% \pm 0.3	3.5% \pm 2.2
RT + PBS + anti-PD-L1	36.2% \pm 11.3	3.1% \pm 2.7	1.5% \pm 0.3	1.6% \pm 1.0	5.4% \pm 2.5
RT + L19-IL2 + anti-PD-L1	33.2 \pm 10.2	4.3% \pm 2.4	0.7% \pm 0.3	1.5% \pm 1.1	2.8% \pm 1.4

mDCs: mature dendritic cells.